基于NT-proBNP和心电图的房颤系统筛查随机邀请研究:STROKESTOP II
在瑞典斯德哥尔摩地区,将75至76岁人群随机分为筛查邀请组和对照组,筛查组先测NT-proBNP,低值者仅做单次单导联心电图,高值者进行为期2周的延长筛查。中位随访5.1年后,两组卒中或系统性栓塞风险无差异(HR 0.96,95%CI 0.86-1.06);低NT-proBNP组卒中或系统性栓塞风险显著低于对照组(HR 0.59,95%CI 0.46-0.74)。
要点
- NT-proBNP指导的房颤筛查未降低总体卒中或系统性栓塞风险。
- 低NT-proBNP者放弃延长筛查是安全的,且卒中风险更低。
- 高NT-proBNP者卒中或系统性栓塞风险高于低NT-proBNP者。
核心结论
- 在基于人群的房颤筛查试验中,使用NT-proBNP增强筛查的干预组与对照组相比,卒中或系统性栓塞风险无差异。
- 使用NT-proBNP识别低风险参与者并使其免于延长筛查是安全的。
研究设计与样本
- 随机对照试验,纳入瑞典斯德哥尔摩地区所有75岁和76岁个体,按1:1随机分为筛查邀请组和对照组。
- 筛查组测量NT-proBNP,若NT-proBNP<125 ng/L则仅注册一次单导联心电图;若NT-proBNP≥125 ng/L则进行为期2周的延长筛查,每日记录单导联心电图4次。
- 共28 712人随机,排除死亡和移居后,干预组13 905人,对照组13 884人;干预组参与率为49.2%(6843/13 905)。
主要发现
- 干预组新检出房颤比例为2.4%(165/6843)。
- 随访5年后,干预组与对照组房颤患病率或口服抗凝治疗无差异。
- 中位随访5.1年(四分位距5.0-5.8),主要结局卒中或系统性栓塞在干预组与对照组间无差异(HR 0.96,95%CI 0.86-1.06)。
- 低NT-proBNP组卒中或系统性栓塞显著少于对照组(HR 0.59,95%CI 0.46-0.74;P<0.001)。
- 高NT-proBNP组卒中或系统性栓塞风险高于低NT-proBNP组(HR 1.57,95%CI 1.22-2.02;P=0.001)。
关键数值与推荐
- NT-proBNP<125 ng/L者仅做单次单导联心电图,NT-proBNP≥125 ng/L者进行2周延长筛查(每日4次单导联心电图)。
- 高NT-proBNP组(NT-proBNP≥125 ng/L)且无既往房颤者占总人数60%,接受延长筛查。
临床怎么用
- 对于75至76岁人群,采用NT-proBNP指导的房颤筛查策略未显示可降低总体卒中或系统性栓塞风险。
- NT-proBNP低水平者可安全地免于延长筛查,且其卒中或系统性栓塞风险较低。
- NT-proBNP高水平者卒中或系统性栓塞风险较高,需更积极评估与管理。
局限性
- 干预组参与率仅为49.2%,可能影响筛查效果。
- 随访5年后干预组与对照组房颤患病率无差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines have suggested screening for atrial fibrillation to enable early treatment and avoid downstream negative clinical events. We aimed to determine whether atrial fibrillation screening potentially enhanced by NT-proBNP (N-terminal pro-B-type natriuretic peptide) would reduce stroke or systemic embolism incidence compared with a control group and to determine whether it was safe for those with low NT-proBNP concentrations to forfeit prolonged screening. METHODS: In this randomized controlled trial, all 75- and 76-year-old individuals in Stockholm Region, Sweden, were randomized 1:1 to be invited to screening or serve as a control group. NT-proBNP concentrations were measured, and a single-lead ECG was registered only once if NT-proBNP <125 ng/L, whereas if NT-proBNP ≥125 ng/L, participants underwent prolonged screening, recording single-lead ECGs 4 times daily for 2 weeks. If atrial fibrillation was detected, treatment was initiated. Baseline and outcome data were collected from Swedish National Registries. RESULTS: In total, 28 712 individuals were randomized. After exclusion of death and emigration, 13 905 remained in the intervention group, 13 884 in the control group. The participation rate in the intervention group was 49.2% (6843 of 13 905). Participants in the high NT-proBNP group (NT-proBNP≥125 ng/L) without previous atrial fibrillation constituted 60% of the total and underwent prolonged screening. New atrial fibrillation was detected in 2.4% (165 of 6843) in the intervention group. There was no difference in atrial fibrillation prevalence or oral anticoagulant treatment between the intervention and the control group after 5 years of follow-up. After a median of 5.1 years (interquartile range, 5.0-5.8), there was no difference in the primary outcome of stroke or systemic embolism between the intervention group and the control group (hazard ratio, 0.96 [95% CI, 0.86-1.06]). The low NT-proBNP group had significantly fewer strokes or systemic emboli than the control group (hazard ratio, 0.59 [95% CI, 0.46-0.74]; P<0.001). In the high NT-proBNP group, the risk of stroke or systemic embolism was higher compared with the low NT-proBNP group (hazard ratio, 1.57 [95% CI, 1.22-2.02]; P=0.001). CONCLUSIONS: In this population-based screening trial for atrial fibrillation using NT-proBNP for screening enhancement, there was no difference in risk of stroke or systemic embolism for the intervention group compared with controls. Participation was moderate. The use of NT-proBNP for screening enhancement was safe in identifying low-risk participants. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02743416.
引用
- Kemp Gudmundsdottir, Svennberg, Friberg, et al. Randomized Invitation to Systematic NT-proBNP and ECG Screening in 75-Year-Olds to Detect Atrial Fibrillation: STROKESTOP II. Circulation. 2024. PMID: 39217615. doi:10.1161/CIRCULATIONAHA.124.071176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。